Skip to main content
Premium Trial:

Request an Annual Quote

Waters Acquires Chromatography Instrument Maker

NEW YORK (GenomeWeb News) – Waters has acquired privately held Thar Instruments for an undisclosed sum, the Milford, Mass., maker of chromatography and mass spectrometry instruments said after the close of the market on Monday.

Thar makes supercritical fluid chromatography instrument systems that are used for separation, isolation, and quantification of chemical compounds. According to Waters, the technology is similar to liquid chromatography but uses carbon dioxide as the main mobile phase, which offers environmental and cost benefits compared to liquid chromatography solvents.

"By combining Thar's advanced SFC instrumentation with Waters' chromatography expertise, Waters is committed to bringing the benefits of SFC to more laboratories for analytical and purification technologies worldwide," Rohit Khanna, vice president of worldwide marketing for Waters, said in a statement.

Waters had made an equity investment in Pittsburgh-based Thar in June 2007.

Thar had revenues of roughly $18 million in 2008, and Waters expects the acquisition to be neutral to its earnings in 2009.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.